zoledronic acid has been researched along with Genito-urinary Cancer in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anido, U; Climent, MA; Méndez-Vidal, MJ; Puente, J | 1 |
| Atenafu, EG; Joshua, AM; Knox, JJ; Lun, G; Sridhar, SS; Tannock, IF | 1 |
| Fujii, Y; Fukui, I; Masuda, H; Uehara, S; Yamamoto, S; Yamasaki, M; Yonese, J; Yuasa, T | 1 |
| Mulders, P; Saad, F | 1 |
| Henk, HJ; Kaura, S | 1 |
| Armstrong, AJ; Fizazi, K; Freedland, S; Pienta, K; Saad, F; Saylor, PJ; Smith, MR; Tombal, B | 1 |
| Colombel, M | 1 |
| Cornford, P; Manikandan, R; Mistry, R; Philip, J | 1 |
| Lipton, A; Saad, F | 1 |
| Saad, F | 1 |
5 review(s) available for zoledronic acid and Genito-urinary Cancer
| Article | Year |
|---|---|
Zoledronic acid in genitourinary cancer.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Quality of Life; Urogenital Neoplasms; Zoledronic Acid | 2013 |
Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers.
Topics: Animals; Antineoplastic Agents; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Male; Prostate; Prostatic Neoplasms; Urogenital Neoplasms; Urogenital System; Zoledronic Acid | 2012 |
New and emerging therapies for bone metastases in genitourinary cancers.
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma; Denosumab; Diphosphonates; Female; Humans; Imidazoles; Kidney Neoplasms; Male; Prospective Studies; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Randomized Controlled Trials as Topic; RANK Ligand; Urinary Bladder Neoplasms; Urogenital Neoplasms; Urothelium; Zoledronic Acid | 2013 |
[The role of bisphosphonates in the treatment of bone metastases from urogenital cancer ].
Topics: Bone Neoplasms; Diphosphonates; Humans; Imidazoles; Kidney Neoplasms; Male; Molecular Structure; Prostatic Neoplasms; Urogenital Neoplasms; Zoledronic Acid | 2003 |
New research findings on zoledronic acid: survival, pain, and anti-tumour effects.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Urogenital Neoplasms; Zoledronic Acid | 2008 |
5 other study(ies) available for zoledronic acid and Genito-urinary Cancer
| Article | Year |
|---|---|
Use of a clinical assistant to screen patients with genitourinary cancer to encourage entry into clinical trials and use of supportive medication: a pilot project at a Canadian cancer center.
Topics: Antibodies, Monoclonal, Humanized; Bone and Bones; Calcium; Canada; Clinical Trials as Topic; Denosumab; Diphosphonates; Humans; Imidazoles; Patient Acceptance of Health Care; Patient Selection; Prospective Studies; Retrospective Studies; Urogenital Neoplasms; Vitamin D; Zoledronic Acid | 2013 |
Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Comparative Effectiveness Research; Denosumab; Diphosphonates; Humans; Imidazoles; Japan; Kidney Function Tests; Male; Middle Aged; Neoplasm Staging; Outcome and Process Assessment, Health Care; Retrospective Studies; Urogenital Neoplasms; Zoledronic Acid | 2016 |
Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Male; Middle Aged; Outcome Assessment, Health Care; Survival Analysis; United States; Urogenital Neoplasms; Zoledronic Acid | 2012 |
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
Topics: Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Magnesium Deficiency; Urogenital Neoplasms; Zoledronic Acid | 2006 |
Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Diphosphonates; Humans; Imidazoles; Magnesium Deficiency; Male; Prostatic Neoplasms; Urogenital Neoplasms; Zoledronic Acid | 2006 |